2023
Review of the role of the endogenous opioid and melanocortin systems in the restless legs syndrome
Walters A, Li Y, Koo B, Ondo W, Weinstock L, Champion D, Afrin L, Karroum E, Bagai K, Spruyt K. Review of the role of the endogenous opioid and melanocortin systems in the restless legs syndrome. Brain 2023, 147: 26-38. PMID: 37633259, PMCID: PMC10796165, DOI: 10.1093/brain/awad283.Peer-Reviewed Original ResearchConceptsRestless legs syndromeMu-opioid receptorsRLS patientsEndogenous opioidsLegs syndromeOpioid receptorsSerum ironΒ-endorphinMelanocortin systemIdiopathic restless legs syndromeRLS-like symptomsPeriodic limb movementsLow serum ironWild-type miceSensory changesMelanocyte stimulating hormoneReceptor blockersSerum ferritinAutopsy studyStriatal dopamineAdrenocorticotropic hormoneStimulating hormoneDopaminergic systemMouse modelTherapeutic efficacy
2022
Re-equip with opioids instead of dopamine agonists for the treatment of augmentation
Koo B. Re-equip with opioids instead of dopamine agonists for the treatment of augmentation. Sleep 2022, 45: zsac115. PMID: 35556146, DOI: 10.1093/sleep/zsac115.Peer-Reviewed Original Research